Key Points
- CEO Larry Wood purchased 23,900 PROCEPT BioRobotics shares at an average price of $20.85, investing approximately $498,315 in the open-market transaction.
- PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year and above estimates, but its $0.47 per-share loss slightly exceeded expectations; the company remains unprofitable.
- Analyst sentiment is cautious, with multiple downgrades and a consensus “Hold” rating. The company also faces securities-litigation allegations involving product demand and customer inventory, adding uncertainty despite strong institutional ownership of 89.46%.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) CEO Larry Wood bought 23,900 shares of PROCEPT BioRobotics stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer directly owned 23,900 shares of the company's stock, valued at approximately $498,315. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
PROCEPT BioRobotics Stock Performance
Shares of PRCT opened at $21.71 on Tuesday. The company's fifty day moving average is $21.47 and its 200-day moving average is $24.69. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $42.71. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -11.19 and a beta of 0.89. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm's revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.35) EPS. Equities analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.
Institutional Trading of PROCEPT BioRobotics
Several institutional investors have recently made changes to their positions in PRCT. Caitong International Asset Management Co. Ltd raised its position in PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock worth $29,000 after purchasing an additional 746 shares in the last quarter. Versant Capital Management Inc boosted its holdings in PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company's stock valued at $27,000 after purchasing an additional 1,084 shares in the last quarter. Center for Financial Planning Inc. acquired a new stake in PROCEPT BioRobotics during the fourth quarter valued at approximately $40,000. US Bancorp DE grew its stake in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company's stock valued at $60,000 after purchasing an additional 1,079 shares during the period. Finally, Cache Advisors LLC bought a new stake in shares of PROCEPT BioRobotics in the 1st quarter valued at approximately $42,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.
PROCEPT BioRobotics News Roundup
Here are the key news stories impacting PROCEPT BioRobotics this week:
- Positive Sentiment: CEO Larry L. Wood purchased 23,900 shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may improve investor confidence by signaling management believes the shares are undervalued. SEC Form 4 filing
- Neutral Sentiment: Several law firms reminded investors of a September 22, 2026 deadline to seek lead-plaintiff status in a proposed securities class action covering purchases from February 28, 2024, through February 25, 2026. The notices are largely procedural and do not represent new company disclosures, but they keep legal uncertainty in focus. Rosen securities class action notice
- Negative Sentiment: The lawsuit allegations center on potentially misleading statements or omissions regarding product demand, repeated underperformance in unit handpiece sales, and excess customer inventory reportedly built up through late-quarter bulk discounts. The allegations relate to an approximately 18% share-price decline and could create litigation costs, reputational damage, and uncertainty around future sales. Hagens Berman class action notice
- Negative Sentiment: Analysts have reduced their growth views and lowered PROCEPT’s estimated fair value, suggesting concerns about demand momentum and the company’s longer-term expansion prospects. This adds pressure to a stock that remains unprofitable, despite recent revenue growth. Analyst fair value update
Analyst Upgrades and Downgrades
PRCT has been the subject of several recent analyst reports. Leerink Partners downgraded PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $31.00 to $29.00 in a research note on Thursday, June 11th. UBS Group downgraded PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 price objective on the stock. in a research note on Tuesday, July 28th. Citigroup lowered PROCEPT BioRobotics to a "hold" rating in a report on Thursday, July 2nd. Jefferies Financial Group reaffirmed a "hold" rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, TD Cowen lowered their price target on PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of "Hold" and a consensus price target of $28.00.
Check Out Our Latest Research Report on PRCT
About PROCEPT BioRobotics
(
Get Free Report)
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
